AVALO THERAPEUTICS, INC. Increase (Decrease) in Deferred Revenue
AVALO THERAPEUTICS, INC. (AVTX) reported Increase (Decrease) in Deferred Revenue of $102.34 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2017-11-07
- AVALO THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was $45.11K, a 83.37% decline year-over-year.
- AVALO THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was $112.12K.
- AVALO THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was -$54.89K.
- AVALO THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2016-09-30 was $271.23K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month |
|---|---|---|---|
| 2017-09-30 | $45.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $157.23K derived: sum of 2 quarters · filed 2017-11-07 | $102.34K 10-Q · filed 2017-11-07 |
| 2017-06-30 | $112.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $57.23K 10-Q · filed 2017-08-14 | |
| 2017-03-31 | -$54.89K 10-Q · filed 2017-05-09 | ||
| 2016-09-30 | $271.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$379.26K derived: sum of 2 quarters · filed 2017-11-07 | -$379.26K 10-Q · filed 2017-11-07 |
| 2016-06-30 | -$650.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$650.49K 10-Q · filed 2017-08-14 | |
| 2016-03-31 | $0.00 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |